Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Maceron Jul 03, 2019 12:59pm

132 Views

Post# 29883732

RE:RE:RE:RE:RE: KO PUNCH

Yes, the odds are much more favourable for a headline result with the first cohort of patients due to the definitions that will be used for phase 2. Written and approved by people that understand the disease.
Macer

Eoganacht wrote: Given that the "metastatic progression of disease in patient 4 was unrelated to TLD-1433 PDT", and the refined definition of CR for PH2, "similar data to our PH1" would be 100% CR at 360 days!

enriquesuave wrote:
The next AUA meeting will have the entire Urology world excited and intrigued. IMHO. We should have 30-50 patients data and maybe more with some 3, 6 and 9 months data. It will be real if we can get similar data to our PH1. IMHO

fredgoodwinson wrote: Harpos; at 27mins 40 secs into his segment of the AGM Video (in summary) Prof.Jewett states:

"There was a lot of excitement at our investigative meeting held just a month ago in Chicago.

The potential investigators really were quite intrigued,some of them very,very experienced investigators around the world who have been through many Trials."